AMA Announces End of Sustainable Growth Rate Formula

Share this content:
AMA Announces End of Sustainable Growth Rate Formula
AMA Announces End of Sustainable Growth Rate Formula

WEDNESDAY, April 15, 2015 (HealthDay News) -- Recently adopted legislation has repealed the sustainable growth rate (SGR) formula, according to a report published by the American Medical Association (AMA).

Following years of advocacy by physicians, the U.S. Senate passed a bill Tuesday evening to immediately repeal the SGR formula. On the eve of a 21 percent cut to physicians' Medicare payments, the Medicare Access and CHIP Reauthorization Act was adopted. Starting July 1, and lasting through 2019, the bill provides positive annual payment updates of 0.5 percent.

The legislation includes several provisions for physicians such as streamlining and simplification of Medicare's current quality reporting programs into one merit-based incentive payment system; inclusion of protections that prevent medical liability cases from using Medicare quality program standards and measures as a standard or duty of care; and incentive payments for physicians who participate in alternative payment models and meet specific thresholds. In addition, technical support will be provided for smaller practices to participate in alternative payment models or fee-for-service incentive programs.

"Passage of this historic legislation finally brings an end to an era of uncertainty for Medicare beneficiaries and their physicians -- facilitating the implementation of innovative care models that will improve care quality and lower costs," AMA Executive Vice President and Chief Executive Officer James L. Madara, M.D., said in an association news release. "Patients will be able to get the care they need and deserve."

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »